Veranex's Commercial Strategy team partnered with Alcon in 2020 to design and execute a time-and-motion study comparing Alcon's femtosecond laser system against a competitor. The goal of this study was to compare time efficiencies between the two systems, as cataract...
Article by Veranex explores the intersections between Machine Learning and Medical Device Regulations
In this article written by our software regulatory team, we explore how machine learning intersects with medical device development and how the regulatory framework has been evolving to keep up with innovation.
Veranex Presents Study Results at the National Kidney Foundation Spring Clinical Meeting
Dr. Manasi Datar and colleagues used conjoint analysis to estimate preferences regarding kidney disease testing from 401 PCPs via a web survey. Hypothetical patient profiles created using clinical parameters demonstrated the clinical utility of a novel kidney...
Veranex Supports Retrospective Claims Analysis of Physical Therapy Utilization Among Women With Stress or Mixed Urinary Incontinence
Manasi Datar, Li-Chen Pan, and Thomas Goss, members of the Veranex Commercial Strategy and Market Access team, supported the retrospective claims analysis. The objective of the analysis was to describe the characteristics of women with stress or mixed urinary...
Dasiglucagon Demonstrates Reduced Costs in the Treatment of Severe Hypoglycemia in a Budget Impact Model
Jordan Hinahara and Thomas Goss, members of our Commercial Strategy and Market Access team, contributed to the budget impact model. The objective was to evaluate the economic impact of dasiglucagon compared with available glucagon treatments for SHE management,...
Study by Veranex and Thermo Fisher Highlights Payer Budget Impact of Novel Test for Kidney Transplant Rejection
By developing a U.S. payer budget impact model and associated manuscript for Thermo Fisher’s Molecular Microscope® MMDx®-Kidney (a microarray with machine learning for kidney biopsy interpretation), Veranex supported Thermo Fisher’s efforts to communicate the test’s...
Published Health Economics Study Shows a High Disease Burden Associated with Stress/Mixed Urinary Incontinence to U.S. Payers
Veranex’s Commercial Strategy and Market Access team members, Manasi Datar, PhD, Li-Chen Pan, MPH, and Thomas F. Goss, PharmD, along with members from Renovia, Inc. successfully published a peer-reviewed manuscript in Neurology and Urodynamics highlighting the...
Study by Veranex and Proteomics International Demonstrates Clinical Utility of Prognostic Test for Type 2 Diabetes Patients
By conducting a clinical utility study for Proteomics International’s PromarkerD (a blood-based test that predicts the risk of kidney disease/decline in Type 2 diabetes patients), Veranex provided evidence of the test’s value to physicians and its ability to affect...
Veranex Supports Philips Healthcare with Writing Manuscript of Medicare Claims Study of Mobile Cardiac Monitoring
By leading the manuscript development, Veranex supported Philips Healthcare in publishing real-world evidence data supporting the use of Mobile Cardiac Monitoring after a TAVR procedure.[dpvfw_pdf_viewer_embed _builder_version="4.18.0" _module_preset="default"...
Demonstrating Clinical Utility Using a Validated Methodology From the Market Research Toolkit
Veranex Director Lauren Fusfeld uses a case study to show how conjoint analysis can demonstrate to payers and health care providers the clinical utility of a prognostic test. Lauren's article is featured on page 30.